Literature DB >> 7507891

Septicemia-inducing Escherichia coli O115:K"V165"F165(1) resists killing by porcine polymorphonuclear leukocytes in vitro: role of F165(1) fimbriae and K"V165" O-antigen capsule.

M Ngeleka1, B Martineau-Doizé, J M Fairbrother.   

Abstract

Escherichia coli O115:K"V165":F165(1) wild-type strain 5131 survives in the bloodstream of experimentally inoculated gnotobiotic pigs and induces septicemia, whereas its afimbriate (F165(1)-negative) TnphoA mutant M48 and its acapsular (K"V165"-negative) spontaneous mutant 5131a are both nonpathogenic. We evaluated the role of the mannose-resistant F165(1) fimbrial system and of the O-antigen K"V165" capsule in resistance to phagocytosis by porcine polymorphonuclear leucocytes (PMNLs) in vitro. F165(1)-positive strains (5131 and 5131a) attached to and were ingested by PMNLs at a significantly higher level than afimbrial mutant M48 (P < 0.001) after 1 h of incubation. During incubation of these strains with PMNLs for up to 6 h, parental strain 5131 resisted killing whereas afimbriate mutant M48 and acapsular mutant 5131a were gradually killed and were found at significantly lower numbers than the parental strain 5131 at 2 (P < 0.05) and 6 (P < 0.001) h. When bacteria were opsonized with normal pig serum, the afimbriate and acapsular mutants survived less well than when the bacteria were nonopsonized. Upon examination by electron microscopy of PMNLs after 2 h of incubation with bacteria, structurally normal bacteria were observed more often within phagosomes of PMNLs incubated with the parental strain than within phagosomes of PMNLs incubated with the afimbriate or the acapsular mutant. The extracellular oxidative response (as tested by release of hydrogen peroxide) of PMNLs stimulated by phorbol myristate acetate was completely inhibited by F165(1)-positive strains but only partially inhibited by the afimbriate mutant. These results suggest that the F165(1) fimbrial system may mediate adherence of E. coli O115 to PMNLs. Survival of the parental strain in the presence of PMNLs, which may be intracellular, is at least partially due to the presence of the F165(1) fimbrial system and of the O-antigen capsule K"V165". Furthermore, the presence of the F165(1) fimbrial system may contribute to the bacterial inhibition of the oxidative response of porcine PMNLs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507891      PMCID: PMC186121          DOI: 10.1128/iai.62.2.398-404.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

Review 1.  Phagocyte lysosomes: interactions with infectious agents, phagosomes, and experimental perturbations in function.

Authors:  M B Goren
Journal:  Annu Rev Microbiol       Date:  1977       Impact factor: 15.500

2.  Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis.

Authors:  J B Robbins; G H McCracken; E C Gotschlich; F Orskov; I Orskov; L A Hanson
Journal:  N Engl J Med       Date:  1974-05-30       Impact factor: 91.245

3.  Influence of adhesins on the interaction of Escherichia coli with human phagocytes.

Authors:  C Svanborg Edén; L M Bjursten; R Hull; S Hull; K E Magnusson; Z Moldovano; H Leffler
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

Review 4.  Perturbation of the normal mechanisms of intraleukocytic killing of bacteria.

Authors:  P G Quie
Journal:  J Infect Dis       Date:  1983-08       Impact factor: 5.226

5.  Phagocyte strategy vs. microbial tactics.

Authors:  P Densen; G L Mandell
Journal:  Rev Infect Dis       Date:  1980 Sep-Oct

6.  Participation of immunoglobulins and complement components in the intracellular killing of Staphylococcus aureus and Escherichia coli by human granulocytes.

Authors:  P C Leijh; M T van den Barselaar; M R Daha; R van Furth
Journal:  Infect Immun       Date:  1981-09       Impact factor: 3.441

7.  Effect of phorbol myristate acetate on the oxidative metabolism of human polymorphonuclear leukocytes.

Authors:  L R DeChatelet; P S Shirley; R B Johnston
Journal:  Blood       Date:  1976-04       Impact factor: 22.113

8.  Interaction of Escherichia coli with different fimbriae and polymorphonuclear leukocytes.

Authors:  B Björkstén; T Wadström
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

Review 9.  Oxygen-dependent and oxygen-independent mechanisms of microbicidal activity of neutrophils.

Authors:  P Elsbach; J Weiss
Journal:  Immunol Lett       Date:  1985       Impact factor: 3.685

10.  Serum-resistant mutants of Escherichia coli O111 contain increased lipopolysaccharide, lack an O antigen-containing capsule, and cover more of their lipid A core with O antigen.

Authors:  R C Goldman; K Joiner; L Leive
Journal:  J Bacteriol       Date:  1984-09       Impact factor: 3.490

View more
  4 in total

1.  Lack of a role of cytotoxic necrotizing factor 1 toxin from Escherichia coli in bacterial pathogenicity and host cytokine response in infected germfree piglets.

Authors:  S Fournout; C M Dozois; M Odin; C Desautels; S Pérès; F Hérault; F Daigle; C Segafredo; J Laffitte; E Oswald; J M Fairbrother; I P Oswald
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Monitoring F1651 P-like fimbria expression at the single-cell level reveals a highly heterogeneous phenotype.

Authors:  Richard Graveline; Rémi Lavoie; Philippe Garneau; France Daigle; Serge Sénéchal; Christine Martin; Josée Harel
Journal:  Infect Immun       Date:  2015-02-23       Impact factor: 3.441

3.  Pathogenic role of SEF14, SEF17, and SEF21 fimbriae in Salmonella enterica serovar enteritidis infection of chickens.

Authors:  G Rajashekara; S Munir; M F Alexeyev; D A Halvorson; C L Wells; K V Nagaraja
Journal:  Appl Environ Microbiol       Date:  2000-04       Impact factor: 4.792

4.  Pseudomonas aeruginosa selective adherence to and entry into human endothelial cells.

Authors:  M C Plotkowski; A M Saliba; S H Pereira; M P Cervante; O Bajolet-Laudinat
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.